M Roach

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
    Colleen A Lawton
    Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Int J Radiat Oncol Biol Phys 69:646-55. 2007
  2. ncbi Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1708, USA
    Cancer 109:213-20. 2007
  3. ncbi Goserelin acetate in combination with radiotherapy for prostate cancer
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California 94143 1708, USA
    Expert Opin Pharmacother 8:257-64. 2007
  4. ncbi Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials
    Mack Roach
    Department of Radiation Oncology, Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143, USA
    J Urol 176:S16-20. 2006
  5. ncbi Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial
    Mack Roach
    University of California San Francisco, San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 66:647-53. 2006
  6. ncbi Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:965-74. 2006
  7. ncbi Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials
    - Roach M 3RD
    Departments of Radiation Oncology, Medical Oncology and Urology, University of California San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 47:617-27. 2000
  8. ncbi Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials
    M Roach
    Departments of Radiation Oncology, Medical Oncology, and Urology, University of California San Francisco, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 47:609-15. 2000
  9. ncbi Spectroscopy in prostate cancer: hope or hype?
    M Roach
    Department of Radiation Oncology, University of California, Mt Zion Cancer Center, San Francisco 94115, USA
    Oncology (Williston Park) 15:1399-410; discussion 1415-6, 1418. 2001
  10. ncbi Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study
    Mack Roach
    University of California San Francisco, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 60:1351-6. 2004

Research Grants

  1. SFSU/UCSF Comprehensive Cancer Partnership Program
    Mack Roach; Fiscal Year: 2007

Collaborators

Detail Information

Publications99

  1. ncbi An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
    Colleen A Lawton
    Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Int J Radiat Oncol Biol Phys 69:646-55. 2007
    ..This trial was also designed to test the hypothesis that neoadjuvant hormonal therapy (NHT) followed by concurrent total androgen suppression and RT improves PFS compared with RT followed by adjuvant hormonal therapy (AHT) by > or =10%...
  2. ncbi Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1708, USA
    Cancer 109:213-20. 2007
    ..In this article, the authors summarize arguments for incorporating additional pretreatment parameters and creating a new staging system for prostate cancer...
  3. ncbi Goserelin acetate in combination with radiotherapy for prostate cancer
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California 94143 1708, USA
    Expert Opin Pharmacother 8:257-64. 2007
    ..The reduction in deaths from prostate cancer noted in the mid-1990s may largely be due to the early use of these agents in men with intermediate-to-high-risk disease...
  4. ncbi Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials
    Mack Roach
    Department of Radiation Oncology, Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143, USA
    J Urol 176:S16-20. 2006
    ..We developed a model for determining disease specific survival in prostate cancer...
  5. ncbi Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial
    Mack Roach
    University of California San Francisco, San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 66:647-53. 2006
    ..To avoid a timing bias, this analysis was limited to patients receiving neoadjuvant and concurrent hormonal therapy (N&CHT) in Arms 1 and 2 of the study...
  6. ncbi Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:965-74. 2006
    ..For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature...
  7. ncbi Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials
    - Roach M 3RD
    Departments of Radiation Oncology, Medical Oncology and Urology, University of California San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 47:617-27. 2000
    ..To assess the impact of short-term and long-term androgen suppression on the disease-specific and overall survival of 2200 men treated with radiotherapy on one of 5 prospective randomized trials when stratified by prognostic risk groups...
  8. ncbi Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials
    M Roach
    Departments of Radiation Oncology, Medical Oncology, and Urology, University of California San Francisco, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 47:609-15. 2000
    ..In this analysis we combine these three factors to define prognostic subgroups that correlate with disease-specific survival (DSS) death from prostate cancer...
  9. ncbi Spectroscopy in prostate cancer: hope or hype?
    M Roach
    Department of Radiation Oncology, University of California, Mt Zion Cancer Center, San Francisco 94115, USA
    Oncology (Williston Park) 15:1399-410; discussion 1415-6, 1418. 2001
    ..Additional studies will reveal both the positive aspects and clinical challenges of MRI/..
  10. ncbi Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study
    Mack Roach
    University of California San Francisco, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 60:1351-6. 2004
    ..To assess the relationship between the dose to the bulb of the penis and the risk of impotence in men treated on Radiation Therapy Oncology Group (RTOG) 9406...
  11. ncbi Treatment margins and prostate brachytherapy: "size matters," but how much and where?
    Mack Roach
    Departments of Radiation Oncology and Urology, University of California San Francisco, UCSF/Mt Zion NCI-Designated Comprehensive Cancer Center, 1600 Divisadero Street, Suite H-1031, San Francisco, CA 94143-1708, USA
    Cancer J 10:158-9. 2004
  12. ncbi Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer
    Mack Roach
    Department of Radiation Oncology, University of California, San Francisco, UCSF Mt Zion NCI Designated Comprehensive Cancer, 1600 Divisadero Street, San Francisco, CA 94143 1708, USA
    Urol Clin North Am 31:353-66. 2004
    ..Finally, the role of radiation protectors is beginning to be addressed. It is hoped that these advances will eliminate toxicity associated with radiotherapy and increase cure rates...
  13. ncbi Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413
    M Roach
    University of California San Francisco, 1600 Divisadero St, Suite H1031, San Francisco, CA 94143 1708, USA
    J Clin Oncol 21:1904-11. 2003
    ..This trial also tested the hypothesis that neoadjuvant and concurrent hormonal therapy (NCHT) improves PFS compared with adjuvant hormonal therapy (AHT) by 10%...
  14. ncbi Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long?
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, 94143 1708, USA
    J Urol 170:S35-40; discussion S40-1. 2003
    ..The results from recent randomized trials were used to identify subpopulations of patients most likely to benefit from long versus short-term hormonal therapy with external beam radiotherapy...
  15. ncbi The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 45:1143-9. 1999
    ..The purpose of this study is to analyze the impact of age, histology, Karnofsky performance status (KPS), and specific toxicities on the median survival time (MST) and quality-adjusted survival (QTime) for each treatment strategy...
  16. ncbi Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials
    Mack Roach
    Department of Radiation Oncology, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1708, USA
    J Urol 169:245-50. 2003
    ..We noted no evidence that race has independent prognostic significance in patients treated for prostate cancer in Radiation Therapy Oncology Group prospective randomized trials...
  17. ncbi What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?
    K D DeWitt
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143-1708, USA
    Urology 62:492-6. 2003
    ..Longer follow-up and larger patient numbers are required to confirm these observations...
  18. ncbi The use of megavoltage cone-beam CT to complement CT for target definition in pelvic radiotherapy in the presence of hip replacement
    M Aubin
    Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Br J Radiol 79:918-21. 2006
    ..This short communication presents the use of a new imaging modality, megavoltage cone-beam CT, to complement the regular CT for target definition of prostate cancer treatment of patients with hip replacements...
  19. ncbi 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review
    J B Fiveash
    Department of Radiation Oncology, University of Alabama Birmingham Medical Center, Birmingham, AL 35233, USA
    Int J Radiat Oncol Biol Phys 47:335-42. 2000
    ....
  20. ncbi Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10
    William U Shipley
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 64:1162-7. 2006
    ....
  21. ncbi Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II
    Jeff M Michalski
    Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 56:192-8. 2003
    ..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
  22. ncbi Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer
    M Roach
    Department of Radiation Oncology, University of California, San Francisco 94143 0226, USA
    Eur Urol 32:48-54. 1997
    ....
  23. ncbi Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy
    B Pickett
    University of California, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 44:921-9. 1999
    ....
  24. ncbi Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02
    A Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 22:2133-40. 2004
    ....
  25. ncbi Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer
    B M Fisch
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, California, USA
    Urology 57:955-9. 2001
    ..If confirmed, these data suggest that by using three-dimensional-based treatment planning and carefully designed treatment fields, the potency of men treated with radiotherapy might be substantially improved...
  26. ncbi Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation
    I C Hsu
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 46:851-8. 2000
    ....
  27. ncbi Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer
    H K Shu
    Department of Radiation Oncology, University of California, San Francisco, California, USA
    Urology 57:102-7. 2001
    ..CONCLUSIONS: Doses of 82 Gy or more to a portion of the prostate gland can be tolerated with acceptable morbidity. This observation supports the continued investigation of IMRT as a means for improving disease control in prostate cancer...
  28. ncbi Prostate volumes and organ movement defined by serial computerized tomographic scans during three-dimensional conformal radiotherapy
    M Roach
    Department of Radiation Oncology, University of California, San Francisco UCSF, UCSF Mt Zion Cancer Center, USA
    Radiat Oncol Investig 5:187-94. 1997
    ..Efforts should be directed at improving our ability to reduce organ movement and accurately targeting the prostate...
  29. ncbi Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
    O E Streeter
    Department of Radiation Oncology, University of Southern California, Los Angeles 90033 0804, USA
    Int J Radiat Oncol Biol Phys 44:1047-52. 1999
    ....
  30. ncbi Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate
    Mack Roach
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143-1708, USA
    Urology 61:730-5. 2003
    ..CONCLUSIONS: The pPSA level is an independent predictor of survival in patients initially treated with radiotherapy alone...
  31. ncbi Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 59:1053-61. 2004
    ..To report changing trends in external beam radiotherapy (EBRT) delivery practice for clinically localized prostate cancer as determined from the 1999 survey from the American College of Radiology National Patterns of Care Study...
  32. ncbi Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost
    Siavash Jabbari
    Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 76:36-42. 2010
    ..We studied the biochemical control (biochemical no evidence of disease [bNED]) and prostate-specific antigen (PSA) nadir achieved with contemporary PPI, and evaluated it against 3D-CRT and CPBRT...
  33. ncbi Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10
    William U Shipley
    Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 54:1302-10. 2002
    ....
  34. ncbi Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer
    Barby Pickett
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:1047-55. 2004
    ....
  35. ncbi Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy
    Daniel C Schiffner
    Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 67:610-9. 2007
    ..The aim of this study was to measure interfraction prostate bed motion, setup error, and total positioning error in 10 consecutive patients undergoing postprostatectomy radiotherapy...
  36. ncbi The evolving role of pelvic radiation therapy
    Terence Roberts
    Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143-1708, USA
    Semin Radiat Oncol 13:109-20. 2003
    ..For most other solid tumors, the regional lymph nodes are routinely treated by some modality, so it is not surprising that WPRT might benefit a subset of high-risk patients...
  37. ncbi Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes
    Ping Xia
    Department of Radiation Oncology, University of California San Francisco, San Francisco, California 94143, USA
    Med Phys 37:5006-13. 2010
    ..The purposes of this article are to propose a new management strategy and to compare this strategy to the conventional isocenter shift method and the previously proposed MLC-shifting method...
  38. ncbi Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy
    P Xia
    Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 51:244-54. 2001
    ..6 Gy, while keeping the doses to the rectum and the bladder significantly lower than those associated with a Grade 2 complication rate of 10%...
  39. ncbi The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
    A R Gottschalk
    Department of Radiation Oncology and the Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, H 1031, San Francisco, CA 94115, USA
    Br J Cancer 90:950-4. 2004
    ..This minireview will address the largest and most influential of these trials, and attempt to guide physicians in selecting the appropriate patients for this combined approach...
  40. ncbi [Megavoltage cone-beam CT: Recent developments and clinical applications]
    J Pouliot
    Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143, USA
    Cancer Radiother 10:258-68. 2006
    ..Examples of the image-guided treatment process from the acquisition of the MV CBCT scan to the correction of the couch position and dose delivery will be presented for spinal and lung lesions and for head and neck, and prostate cancers...
  41. ncbi Influence of number of CAG repeats on local control in the RTOG 86-10 protocol
    May Abdel-Wahab
    Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
    Am J Clin Oncol 29:14-20. 2006
    ..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)...
  42. ncbi Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy
    Tim Joseph
    Department of Radiology, University of California San Francisco, San Francisco, CA 94143 0628, USA
    Int J Radiat Oncol Biol Phys 73:665-71. 2009
    ....
  43. ncbi Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience
    Brian Lee
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 67:1106-12. 2007
    ..The aim of this study was to evaluate the feasibility and safety of salvage high-dose-rate (HDR) brachytherapy for locally recurrent prostate cancer after external beam radiotherapy (EBRT)...
  44. ncbi Stage II (N1) lung cancer
    O Choy
    Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California, USA
    Chest Surg Clin N Am 11:39-59, viii. 2001
    ..This survival will be achieved through early detection and combined treatments using effective surgical interventions, improved radiotherapeutics, and especially significantly enhanced, rationally designed systemic therapies...
  45. ncbi Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy
    Arjun Sahgal
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA94143, USA
    Int J Radiat Oncol Biol Phys 72:247-54. 2008
    ..To compare the urethral and prostate absolute and biologic effective doses (BEDs) for 131 Cs and 125 I prostate permanent implant brachytherapy (PPI)...
  46. ncbi Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy
    W Robert Lee
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1030, USA
    Int J Radiat Oncol Biol Phys 54:457-61. 2002
    ..To compare the prostate gland volumes and subsequent quantifiers of implant adequacy determined by five separate brachytherapists on postimplant CT images performed 1 day after prostate brachytherapy...
  47. ncbi Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response
    Eric J Small
    Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    Semin Oncol 29:264-73. 2002
    ....
  48. ncbi Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Mack Roach
    Department of Radiation Oncology and Urology, University of California San Francisco, UCSF Comprehensive Cancer Center, San Francisco 94143 1708, USA
    Strahlenther Onkol 183:26-8. 2007
    ..This review compares both approaches and the rationale for using both...
  49. ncbi Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer
    Alice Wang-Chesebro
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 66:654-62. 2006
    ....
  50. ncbi Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer
    Linda W Chan
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 72:69-77. 2008
    ..The purpose of this study was to develop these constraints, demonstrate that they are achievable, and assess the corresponding rectal toxicity...
  51. ncbi High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience
    Siavash Jabbari
    Department of Radiation Oncology, University of California San Francisco, 94115, USA
    Brachytherapy 8:339-44. 2009
    ..In this report, we describe our technique and early experience with definitive HDR brachytherapy in patients post APR and pelvic EBRT...
  52. ncbi Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, 1600 Divisadero St, Suite H1031, San Francisco, CA 94143 1708, USA
    J Clin Oncol 26:585-91. 2008
    ..This report summarizes long-term follow-up results...
  53. ncbi Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions
    Mack Roach
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Surg Oncol 103:587-601. 2011
    ..We provide clinical data that demonstrate how these evolving strategies have the potential to transform treatment paradigms...
  54. ncbi Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study
    Michael W Lometti
    Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Med Dosim 33:22-9. 2008
    ..In most circumstances, with exceptions such as morbidly obese patients, acquisition of only a LAT image for daily targeting of the prostate will provide adequate positional precision...
  55. ncbi State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma
    R Scott Bermudez
    University of California, San Francisco, Department of Radiation Oncology, 1600 Divisadero Street, Suite number H1031, San Francisco, CA 94115, USA
    Future Oncol 3:103-11. 2007
    ..We have also learnt how to optimize the use of prostate-specific antigen to better determine success and failure following radiotherapy...
  56. ncbi Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy
    Joycelyn L Speight
    Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115 1708, USA
    J Clin Oncol 25:987-95. 2007
    ....
  57. ncbi Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 69:79-87. 2007
    ..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
  58. ncbi Radiotherapy in the management of common genitourinary malignancies
    Joycelyn L Speight
    Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, H1031, 1600 Divisadero Street, San Francisco, CA 94143, USA
    Hematol Oncol Clin North Am 20:321-46. 2006
    ....
  59. ncbi Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level
    Barby Pickett
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 65:65-72. 2006
    ..Recent studies have suggested that the treatment of low-risk prostate cancer yields similar results for patients treated with 3D-CRT or PPI...
  60. ncbi (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device
    Jean Pouliot
    Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 56:862-6. 2003
    ..Radiopaque gold markers can be implanted in the prostate to visualize its position on portal images during radiation therapy. This procedure assumes that the markers do not move within the prostate. In this work we test this assumptiom...
  61. ncbi Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV
    Jeff M Michalski
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA
    Int J Radiat Oncol Biol Phys 58:735-42. 2004
    ..This is the first report of the toxicity outcomes using dose level IV (74 Gy) on Radiation Therapy Oncology Group (RTOG) study 9406 for Stage T1-T2 prostate adenocarcinoma...
  62. ncbi Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer
    Laura Ellen Millender
    Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 59:6-10. 2004
    ..Setup error rather than organ motion appears to be the dominant force in positioning error in obese men...
  63. ncbi The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets
    Andrea Pirzkall
    Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 53:434-42. 2002
    ..To examine the influence of energy and number of beams on nontarget dose when using intensity-modulated radiation therapy (IMRT) to treat deep-seated targets...
  64. ncbi Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging
    Barby Pickett
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143 1708, USA
    Int J Radiat Oncol Biol Phys 59:665-73. 2004
    ..To characterize the time to metabolic atrophy (TMA) after permanent prostate implantation (PPI) using combined MRI and magnetic resonance spectroscopic imaging (MRSI) compared with the time to prostate-specific antigen (PSA) nadir...
  65. ncbi Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient
    Tina Dasgupta
    Department of Radiation Oncology, 1600 Divisadero Street, Suite H1031, San Francisco, California 94102 1708, USA
    Radiat Oncol 6:16. 2011
    ....
  66. ncbi Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection
    Antonio C Westphalen
    Department of Radiology, University of California San Francisco, 505 Parnassus Ave, Box 0628, M 372, San Francisco, CA 94143 0628, USA
    Radiology 256:485-92. 2010
    ..To determine if performing magnetic resonance (MR) spectroscopic imaging, compared with performing T2-weighted MR imaging alone, improves the detection of locally recurrent prostate cancer after definitive external beam radiation therapy...
  67. ncbi Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience
    Fergus V Coakley
    Department of Radiology, University of California San Francisco, 505 Parnassus Ave, Box 0628, M 372, San Francisco, CA 94143 0628, USA
    Radiology 233:441-8. 2004
    ..To evaluate endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging for the depiction of locally recurrent prostate cancer after external beam radiation therapy...
  68. ncbi Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movement
    Yu-Ming Liu
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:470-5. 2004
    ..64 mm, p = 0.004; anteroposterior = 2.24, p = 0.035). CONCLUSIONS: Use of the UG induces a small but clinically insignificant displacement of the prostate when "natural" movement is taken into account...
  69. ncbi Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer
    Mack Roach
    Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 78:1314-22. 2010
    ..We used two large Phase III trials involving androgen deprivation therapy and external beam radiation therapy to assess the significance of a BST...
  70. ncbi Radiation dose-volume effects and the penile bulb
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 76:S130-4. 2010
    ..It is acknowledged that the penile bulb may not be the critical component of the erectile apparatus, but it seems to be a surrogate for yet to be determined structure(s) critical for erectile function for at least some techniques...
  71. ncbi Low-dose megavoltage cone-beam CT for radiation therapy
    Jean Pouliot
    Department of Radiation Oncology, University of California San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 61:552-60. 2005
    ....
  72. ncbi Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer
    Janna Andrews
    Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, California 94143-1708, USA
    Oncology (Williston Park) 19:29-36; discussion 36, 39, 43-4. 2005
    ..The potential role of hormonal therapy in conjunction with brachytherapy without pelvic radiotherapy, is limited by inconclusive data and abbreviated follow-up times...
  73. ncbi Predictive models in external beam radiotherapy for clinically localized prostate cancer
    Mack Roach
    Department of Radiation Oncology, University of California at San Francisco, San Francisco, California, USA
    Cancer 115:3112-20. 2009
    ..Cancer 2009;115(13 suppl):3112-20. (c) 2009 American Cancer Society...
  74. ncbi Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer
    I Chow J Hsu
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, USA
    Brachytherapy 4:202-6. 2005
    ..This is a retrospective review of our experience using high-dose-rate (HDR) brachytherapy boost for prostate cancer...
  75. ncbi Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy
    David S Aaronson
    Department of Urology, University of California, San Francisco, CA 94117, USA
    BJU Int 104:600-4. 2009
    ....
  76. ncbi Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions
    Joycelyn L Speight
    Department of Radiation Oncology, UCSF Mt Zion Comprehensive Cancer Center, 1600 Divisadero St H1031, Box 1708, San Francisco, CA 94143 1708, USA
    J Clin Oncol 23:8176-85. 2005
    ..This review is an evidence-based critique of the available treatment approaches considered for the optimal use of radiotherapy as definitive management of clinically localized PCa...
  77. ncbi Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
    J Urol 170:S3-5. 2003
  78. ncbi Evaluation of ultrasound-based prostate localization for image-guided radiotherapy
    K M Langen
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 57:635-44. 2003
    ..However, the occurrence of displacements >/=5 mm was reduced in the AP direction. The inter-user variation of the contour alignment process was significant...
  79. ncbi Role of radiation therapy in the treatment of unfavorable risk prostate cancer
    L W Chan
    Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA 94143-1708, USA
    Minerva Urol Nefrol 58:321-7. 2006
    ..Controversies arise, however, as to what is the best treatment of patients with unfavorable risk prostate cancer. Before addressing this issue, however, it is critical to define unfavorable risk prostate cancer...
  80. ncbi New technologies for the radiotherapy of prostate cancer. A discussion of clinical treatment programs
    J L Meyer
    Department of Radiation Oncology, Saint Francis Memorial Hospital, San Francisco, CA 94109, USA
    Front Radiat Ther Oncol 40:315-37. 2007
  81. ncbi Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V
    Jeff M Michalski
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 62:706-13. 2005
    ..This is the first report of toxicity outcomes at dose Level V (78 Gy) on Radiation Therapy Oncology Group 9406 for Stages T1-T2 adenocarcinoma of the prostate...
  82. ncbi An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes
    Erica Ludlum
    Department of Radiation Oncology, University of California San Francisco, San Francisco, California 94143, USA
    Med Phys 34:4750-6. 2007
    ..0 cm. In order to concurrently treat the prostate and pelvic lymph nodes with the prostate moving independently, shifting selected MLC leaf pairs may be a more practical adaptive solution than shifting the patient...
  83. ncbi Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience
    David A McKenna
    Department of Radiology, University of California, San Francisco, M 372, 505 Parnassus Ave, San Francisco, CA 94143 0628, USA
    Radiology 247:141-6. 2008
    ..To retrospectively determine if pretreatment endorectal magnetic resonance (MR) imaging findings are predictive of outcome in patients who undergo external-beam radiation therapy for prostate cancer...
  84. ncbi Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer
    Sabbir Hossain
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143 1708, USA
    Int J Radiat Oncol Biol Phys 78:58-63. 2010
    ..In particular, the dose gradient across the target and the critical structures such as the rectum and bladder was characterized...
  85. ncbi Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative
    David E Morris
    Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA
    Int J Radiat Oncol Biol Phys 62:3-19. 2005
    ....
  86. ncbi Technique for implantation of fiducial markers in the prostate
    Katsuto Shinohara
    Department of Urology, University of California San Francisco and UCSF Mt Zion Comprehensive Cancer Center, San Francisco, California 94143 0711, USA
    Urology 71:196-200. 2008
    ..To describe our experience in developing a technique for implanting fiducial markers (gold markers and electromagnetic transponders) in the prostate by the transrectal approach under ultrasound guidance...
  87. ncbi The prognostic significance of race and survival from breast cancer: a model for assessing the reliability of reported survival differences
    M Roach
    Dept of Radiation Oncology, University of California, San Francisco 94143 0226, USA
    J Natl Med Assoc 87:214-9. 1995
    ..Efforts directed at early detection and improvements in the quality of care delivered are likely to reduce the excess breast cancer mortality experienced by black women...
  88. ncbi Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma
    Terry T Lee
    Departments of Radiation Oncology, Surgery, and Medicine, University of California, San Francisco, Calif. 94115, USA
    J Thorac Cardiovasc Surg 124:1183-9. 2002
    ..CONCLUSIONS: Radical pleurectomy/decortication with aggressive radiotherapy with or without chemotherapy might offer an alternative treatment option to those who cannot tolerate extrapleural pneumonectomy...
  89. ncbi "Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question?
    Mack Roach
    Int J Radiat Oncol Biol Phys 55:1162-3. 2003
  90. ncbi Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy?
    Mack Roach
    Int J Radiat Oncol Biol Phys 61:1-2. 2005
  91. ncbi Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing"
    Mack Roach
    Int J Radiat Oncol Biol Phys 57:907-9. 2003
  92. ncbi Radiation medicine innovations for the new millenium
    Dwight E Heron
    University of Pittsburgh School of Medicine Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    J Natl Med Assoc 95:55-63. 2003
    ..PRINCIPAL CONCLUSIONS: Significant improvements in technique and equipment have firmly positioned radiotherapy as major artillery in the fight against both benign and malignant diseases...
  93. ncbi Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapy
    Mack Roach
    Int J Radiat Oncol Biol Phys 62:949-50. 2005
  94. ncbi Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era
    Mark Soloway
    Department of Urology, University of Miami School of Medicine, Miami, Florida 33136, USA
    Cancer 104:2310-22. 2005
    ..However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death...
  95. ncbi Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials
    Mack Roach
    J Clin Oncol 26:3816-7; author reply 3817-8. 2008
  96. ncbi Quality of life and satisfaction with outcome among prostate-cancer survivors
    Jennifer S Yu
    N Engl J Med 359:200; author reply 201-2. 2008
  97. ncbi Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406
    Jeff M Michalski
    Washington University Medical School, St Louis, MO 63110, USA
    Semin Radiat Oncol 12:75-80. 2002
    ..Clinical trials should use quality-of-life measures to determine that trade-offs between severity and rates of toxicity are acceptable to patients...
  98. ncbi Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007
    ..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group...
  99. ncbi Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application
    Arjun Sahgal
    Odette Cancer Center of the Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Nat Clin Pract Urol 4:658-70. 2007
    ..We also present our current policies in the treatment of prostate cancer at the University of California, San Francisco...

Research Grants2

  1. SFSU/UCSF Comprehensive Cancer Partnership Program
    Mack Roach; Fiscal Year: 2007
    ..abstract_text> ..